---
title: "ENTA Q2'26 Earnings: revenue estimate is 17.03M USD"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285060876.md"
description: "ENTA (Enanta Pharmaceuticals, Inc.) is set to announce its Q2'26 results on May 11, time not specified. The earnings are expected to be disclosed at 8:00 AM ET (12:00 PM UTC).For Q2'26, revenue estimate is 17.03 million USD with EPS (earnings per share) anticipated at (0.49) USD. Learn more details at .Revenue & EPS values are provided in USDQ2'25Q3'25Q4'25Q1'26Q2'26Revenue Reported14.93 M18.31 M15.12 M18.61 M—Revenue Estimate15.95 M15.54 M15.98 M15.90 M17.03 MRevenue Surprise-6.44%+17.86%-5.32%+17.04%EPS Reported(1.06)(0.85)(0.87)(0.42) EPS Estimate(1.15)(0.90)(1.02)(0.77)(0.49) EPS Surprise+7.56%+5.56%+14.83%+45.29%DisclaimerSelect reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc."
datetime: "2026-05-04T11:00:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285060876.md)
  - [en](https://longbridge.com/en/news/285060876.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285060876.md)
---

# ENTA Q2'26 Earnings: revenue estimate is 17.03M USD

ENTA (Enanta Pharmaceuticals, Inc.) is set to announce its Q2'26 results on May 11, time not specified. The earnings are expected to be disclosed at 8:00 AM ET (12:00 PM UTC).

For Q2'26, revenue estimate is 17.03 million USD with EPS (earnings per share) anticipated at (0.49) USD. Learn more details at .

**Revenue & EPS values are provided in USD**

Q2'25

Q3'25

Q4'25

Q1'26

Q2'26

**Revenue Reported**

14.93 M

18.31 M

15.12 M

18.61 M

—

**Revenue Estimate**

15.95 M

15.54 M

15.98 M

15.90 M

17.03 M

**Revenue Surprise**

\-6.44%

+17.86%

\-5.32%

+17.04%

**EPS Reported**

(1.06)

(0.85)

(0.87)

(0.42)

**EPS Estimate**

(1.15)

(0.90)

(1.02)

(0.77)

(0.49)

**EPS Surprise**

+7.56%

+5.56%

+14.83%

+45.29%

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc.

### Related Stocks

- [ENTA.US](https://longbridge.com/en/quote/ENTA.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)
- [Legend Biotech Q1 Solid for Carvykti, Focus Shifts to In Vivo Pipeline, RBC Says](https://longbridge.com/en/news/286290495.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108 | PALI Stock News](https://longbridge.com/en/news/286156276.md)